haha,.... got it tada.

I hoped for some feedback from some seasoned bio investors on this hub to my earlier post so that I can see more than a SPP of $1, for RVX after the November 16, "AHA 2019" announcement. Therefore, book me in for $1. However, I hope I am proven very much wrong in this regard. 

"Does anyone know of another startup Bio as of late, that failed a phase 3 clinical trial primary outcome measure (top-line), and the SPP propels after the announcement of very positive secondary outcome measures?"  

Koo